Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07636707

QLF4113 in Participants With Metastatic Prostate Cancer

This is an open-label, dose-escalation and expansion Phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, immunogenicity, and preliminary antitumor activity of QLF4113 monotherapy in participants with metastatic prostate cancer.

The Phase I trial consists of two parts: Phase Ia and Phase Ib. Phase Ia is a dose-escalation study of QLF4113 monotherapy to determine the recommended phase two dose and assess safety and PK. Then the study will proceed to Phase Ib, a dose-expansion study to further evaluate the preliminary efficacy and safety of QLF4113 monotherapy under the selected doses.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants voluntarily agree to participate and sign the informed consent form.
  • Male, aged ≥18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
  • Life expectancy ≥ 3 months.
  • Histologically or cytologically confirmed adenocarcinoma of the prostate without evidence of neuroendocrine carcinoma or small cell carcinoma features.
  • Confirmed metastatic Castration-Resistant Prostate Cancer (mCRPC).
  • Failed or are intolerant to standard therapies
  • Adequate function of major organs as defined by the protocol.
  • Agreement to use effective contraception during the study (except for subjects who have undergone bilateral orchiectomy).
  • Prior to the first use of the investigational drug, recovery from all reversible adverse events (AEs) related to prior anticancer treatments

Exclusion criteria

  • Previously treated with drugs targeting CD3 or CD2.
  • Significant Cardiovascular Diseases
  • Active, Uncontrolled Infections
  • Immunosuppressive Treatment before the first dose of the investigational drug
  • Clinically Uncontrolled Third-Space Fluid Accumulation
  • History of Other Malignancies within 5 years prior to the first dose of the investigational drug
  • Moderate to Severe Pulmonary Diseases significantly affecting lung function,
  • Current Hepatic Encephalopathy, Hepatorenal Syndrome, or Cirrhosis classified as Child-Pugh B or worse.
  • Allergy to the Investigational Drug or its Components.
  • Any Condition deemed by the investigator to increase study-related risks, interfere with the interpretation of study results, or otherwise render the participant unsuitable for inclusion.

Treatment and study plan

QLF4113 for injection

Drug

A PSMA/CD3/CD2 antibody

Primary outcomes

  1. Maximum tolerated dose (MTD) (Phase Ia)

    Time frame: From first dose of study treatment until the end of Cycle 1 (21 days)

    Maximum tolerated dose is defined as the previous dose level at which 2 or more out of 2-6 participants experienced a dose-limited toxicity (DLT).

  2. Maximum administered dose (MAD)(Phase Ia)

    Time frame: From first dose of study treatment until the end of Cycle 1 (21 days)

    MAD is defined as follows: a) based on PK data, it is anticipated that at this dose level, the dose-exposure plateau has been reached, b) based on existing safety data, it is judged that dose escalation following this dose level will have a large safety risk or subject intolerance, or c) based on the PK-PD model, it suggested that the optimal target concentration of safety and efficacy has been explored.

  3. recommended phase II dose (RP2D)

    Time frame: Through phase Ia completion, approximately 1 year.

    The RP2D will be comprehensively evaluated based on the safety, PK characteristics, and efficacy data from the Phase Ia study.

  4. The incidence and severity of adverse events (AE) (Phase Ib)

    Time frame: Through phase Ia completion, approximately 1 year.

    Incidence and severity of adverse events (AEs) evaluated according to the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCA) Version 6.0 (v6.0) and American Society for Transplantation and Cellular Therapy (ASTCT)

  5. PSA50 response (Phase Ib)

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

    Best response until progression, as defined by Response Evaluation Criteria in Solid Tumors （RECIST） version (v1.1) and Prostate Cancer Clinical Trials Working Group 3 (PCGW3).

  6. Objective response rate (ORR) (phase Ib)

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

Study contacts

Contact information is provided by the study sponsor or research team.

Jun Guo, Doctor

CONTACT

[email protected]

0086-10- 88121122

Sponsors and collaborators

Lead sponsor

Qilu Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

An Open-label, Multicenter Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of QLF4113 for Injection in Participants With Metastatic Prostate Cancer.

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jun 9, 2026
Registry last updated
Jun 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.